Pharmacodynamics and drug action: Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 5, 2001, Pages 468-474

  Kammerl, Martin C ^a   Nüsing, Rolf M ^a,b,c,d   Schweda, Frank ^a,b,c,d   Endemann, Dierk ^a,b,c,d   Stubanus, Mike ^a,b,c,d   Kees, Frieder ^a,b,c,d   Lackner, Karl J ^a,b,c,d   Fischereder, Michael ^a,b,c,d   Krämer, Bernhard K ^a,b,c,d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RENIN; ROFECOXIB; SODIUM; CREATININE; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SULFONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DRUG SELECTIVITY; HUMAN; KIDNEY FUNCTION; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; SODIUM URINE LEVEL; BLOOD; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION; URINE;

ADULT; ALDOSTERONE; CREATININE; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIET, SODIUM-RESTRICTED; DINOPROSTONE; DIURETICS; FUROSEMIDE; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RENIN; SODIUM; SULFONES;

EID: 0035512256     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.119720     Document Type: Article

References (32)

1. Role of prostaglandins in regulation of kidney function in heart failure
2. Renal prostanoids: Physiological relevance in healthy salt-depleted women
3. Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers
4. Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression
5. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs
6. Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids
7. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation
8. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide
9. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
10. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
11. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
12. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake
13. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
14. Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa
15. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension
16. Regional expression of cylo-oxygenase isoforms in the kidney unilateral ureteral obstruction (UUO)
17. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet
18. COX-2 inhibitors
19. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib)
20. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats
21. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
22. Rofecoxib [Vioxx, MK-0966; 4-(4′methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
23. Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadruple mass spectrometry
24. Effects of experimental salt depletion on urinary prostanoid excretions in normal women
25. Sodium balance, urinary prostaglandin E2 and renin in normal man
26. The influence of dietary sodium on urinary prostaglandin excretion
27. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
28. The effect of chronic sodium depletion on renal function in conscious rats
29. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
30. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
31. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1
32. Abnormal renal sodium handling in cyclooygenase (COX)-1 deficient mice